CNW/ - Takeda Canada Inc. ("Takeda") is pleased to announce positive topline results for the Phase 3, randomized, multicenter ...
Once-daily oral zasocitinib demonstrated statistical superiority over deucravacitinib for all primary and key secondary endpoints in plaque psoriasis study More than 35% of zasocitinib-treated ...
Takeda (TSE:4502/NYSE:TAK) announced positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib (TAK-279), an investigational, next-generation, highly ...
Jun 14, 2026 Jun 14, 2026 Updated Jun 14, 2026 0 ...
The annual Youth LEGO Build Competition, hosted by Tahlequah Area Habitat for Humanity, is returning this summer with major expansions designed to welcome more builders, more families, and greater ...
Objective To evaluate the efficacy and safety of an oral selective tyrosine kinase 2 (TYK2) inhibitor, deucravacitinib, in patients with active psoriatic arthritis (PsA). Methods In this double-blind, ...
23 NIHR University College London Hospitals Biomedical Research Centre, University College London Hospitals (UCLH) NHS Foundation Trust, London, UK Methods Following the EULAR Standardised Operating ...
Contribute to EsmailLeath/Alemdar development by creating an account on GitHub.
Customer stories Events & webinars Ebooks & reports Business insights GitHub Skills ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results